BioCryst Swings to Profit on Robust Revenue Growth

Ticker: BCRX · Form: 10-Q · Filed: Nov 4, 2025 · CIK: 882796

Sentiment: bullish

Topics: Biotechnology, Pharmaceuticals, Rare Disease, Earnings Growth, Debt Management, Hereditary Angioedema, SEC Filing, 10-Q

Related Tickers: BCRX, SHION, GRNC

TL;DR

**BCRX is finally turning a corner, with strong revenue growth driving a net income swing – time to watch for sustained profitability.**

AI Summary

BioCryst Pharmaceuticals Inc. reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, achieving a net income of $18.016 million compared to a net loss of $62.086 million in the prior year period. This improvement was driven by a substantial increase in revenues, which rose to $468.282 million from $319.178 million, representing a 46.7% increase. Operating expenses also increased, with selling, general and administrative expenses climbing to $252.866 million from $185.841 million, and research and development remaining relatively stable at $125.259 million. The company's cash and cash equivalents decreased from $104.713 million at December 31, 2024, to $84.078 million at September 30, 2025, partly due to a $115.847 million repayment of the Pharmakon term loan principal. Total liabilities decreased from $966.354 million to $834.313 million, while total stockholders' deficit improved from $(475.934) million to $(387.889) million. The company also reported a loss on extinguishment of debt of $6.911 million for the nine months ended September 30, 2025.

Why It Matters

This significant swing to profitability for BioCryst Pharmaceuticals is a critical indicator for investors, suggesting improved operational efficiency and market acceptance of its products, particularly ORLADEYO. For employees, it signals greater job security and potential for growth within a more financially stable company. Customers could benefit from continued investment in product development and commercialization. In the broader market, BioCryst's performance could influence investor sentiment towards the rare disease pharmaceutical sector, especially given its competitive landscape with other biotech firms vying for market share in hereditary angioedema (HAE) treatments.

Risk Assessment

Risk Level: medium — While BioCryst achieved net income, its cash and cash equivalents decreased by $20.635 million from December 31, 2024, to September 30, 2025, and it still operates with a substantial stockholders' deficit of $(387.889) million. The company also incurred a $6.911 million loss on extinguishment of debt, indicating ongoing financial restructuring and potential future capital needs, as highlighted in the 'Risk Factor Summary' regarding the need for additional capital.

Analyst Insight

Investors should closely monitor BioCryst's cash flow generation and future debt management strategies. While the shift to profitability is positive, sustained positive cash flow from operations and further reduction of the stockholders' deficit will be crucial for long-term investment confidence.

Financial Highlights

revenue
$468.282M
total Assets
$446.424M
total Debt
$834.313M
net Income
$18.016M
eps
$0.09
cash Position
$84.078M
revenue Growth
+46.7%

Key Numbers

Key Players & Entities

FAQ

What were BioCryst Pharmaceuticals' revenues for the nine months ended September 30, 2025?

BioCryst Pharmaceuticals reported revenues of $468.282 million for the nine months ended September 30, 2025, a substantial increase from $319.178 million in the same period of 2024.

Did BioCryst Pharmaceuticals achieve profitability in the nine months ended September 30, 2025?

Yes, BioCryst Pharmaceuticals achieved a net income of $18.016 million for the nine months ended September 30, 2025, a significant improvement from a net loss of $62.086 million in the prior year period.

How did BioCryst Pharmaceuticals' cash and cash equivalents change during the nine months ended September 30, 2025?

BioCryst Pharmaceuticals' cash and cash equivalents decreased from $104.713 million at December 31, 2024, to $84.078 million at September 30, 2025, reflecting a net decrease of $20.635 million.

What was the impact of debt extinguishment on BioCryst Pharmaceuticals' financials?

BioCryst Pharmaceuticals recognized a loss on extinguishment of debt of $6.911 million for the nine months ended September 30, 2025, which impacted its net income.

What were BioCryst Pharmaceuticals' operating expenses for the nine months ended September 30, 2025?

Total operating expenses for BioCryst Pharmaceuticals were $387.678 million for the nine months ended September 30, 2025, up from $317.213 million in the prior year, primarily driven by increased selling, general and administrative expenses.

What is the status of BioCryst Pharmaceuticals' stockholders' deficit?

BioCryst Pharmaceuticals' total stockholders' deficit improved to $(387.889) million as of September 30, 2025, from $(475.934) million at December 31, 2024, indicating a reduction in negative equity.

What are the key risks highlighted in BioCryst Pharmaceuticals' 10-Q filing?

Key risks include the potential need for additional capital, risks related to a proposed merger, the complexity and uncertainty of product development and regulatory approvals, and heavy reliance on third parties for development and commercialization.

How much did BioCryst Pharmaceuticals repay on its Pharmakon term loan?

BioCryst Pharmaceuticals made a principal repayment of $115.847 million on its Pharmakon term loan during the nine months ended September 30, 2025.

What is ORLADEYO and its significance to BioCryst Pharmaceuticals?

ORLADEYO (berotralstat) is a key product and product candidate for BioCryst Pharmaceuticals, with the company's success depending in part on its commercialization in the United States and elsewhere, and expectations regarding its market.

What was BioCryst Pharmaceuticals' net cash provided by operating activities for the nine months ended September 30, 2025?

BioCryst Pharmaceuticals reported net cash provided by operating activities of $55.409 million for the nine months ended September 30, 2025, a significant positive shift from net cash used in operating activities of $(46.807) million in the prior year.

Risk Factors

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like BioCryst operate in a competitive landscape where innovation and successful commercialization of therapies are crucial for growth. The sector is also subject to evolving reimbursement policies and market access challenges.

Regulatory Implications

As a biopharmaceutical company, BioCryst is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, clinical trial protocols, and marketing practices is paramount. Any failure to meet these regulatory requirements could lead to product delays, recalls, or significant fines, impacting financial performance and market reputation.

What Investors Should Do

  1. Monitor SG&A Expense Growth
  2. Analyze Debt Reduction Strategy
  3. Evaluate Path to Sustained Profitability
  4. Assess Cash Burn and Liquidity

Key Dates

Glossary

Stockholders' Deficit
A negative equity position where a company's total liabilities exceed its total assets. (Indicates the company's financial health and leverage. BioCryst's deficit improved but remains substantial at $(387.889) million.)
Loss on Extinguishment of Debt
A non-recurring charge recognized when a company repays or retires debt before its scheduled maturity date, often due to refinancing at more favorable terms. (BioCryst incurred a $6.911 million loss in this category for the nine months ended September 30, 2025, impacting net income.)
Royalty Financing Obligations
A type of debt where repayment is tied to a percentage of future revenues or profits, often used by pharmaceutical companies to fund development or commercialization. (Represents a significant liability for BioCryst, totaling $439.107 million as of September 30, 2025.)
Secured Term Loan
A loan that is backed by specific collateral, typically used for significant capital expenditures or acquisitions. (BioCryst had a secured term loan of $194.366 million outstanding as of September 30, 2025.)
Accumulated Deficit
The cumulative net losses of a company since its inception that have not been offset by net income. (BioCryst has a large accumulated deficit of $(1,752.024) million, reflecting its history of losses, though it is narrowing.)

Year-Over-Year Comparison

BioCryst Pharmaceuticals Inc. has demonstrated a significant financial turnaround in the nine months ended September 30, 2025, compared to the same period in 2024. Total revenues surged by 46.7% to $468.282 million, driving a substantial swing from a net loss of $62.086 million to a net income of $18.016 million. This improved performance was accompanied by a notable increase in operating expenses, particularly SG&A, and a decrease in cash and cash equivalents due to debt repayment. The company also reduced its total liabilities and improved its stockholders' deficit, though it still remains in a negative equity position.

Filing Stats: 4,645 words · 19 min read · ~15 pages · Grade level 19.2 · Accepted 2025-11-04 16:02:57

Key Financial Figures

Filing Documents

Financial Information

Part I. Financial Information 1

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited): 1 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended Sep tember 30, 2025 and 2024 3 Condensed Consolidated Statements of Stockholders' Deficit for the Three and Nine Months Ended September 30, 2025 and 2024 5 Notes to Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 35

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 49

Controls and Procedures

Item 4. Controls and Procedures 50

Other Information

Part II. Other Information 51

Legal Proceedings

Item 1. Legal Proceedings 51

Risk Factors

Item 1A. Risk Factors 51

Other Information

Item 5. Other Information 82

Exhibits

Item 6. Exhibits 83

Signatures

Signatures 85 Table of Contents When used in this report, unless otherwise indicated, " we, " " our, " " us, " the " Company, " and " BioCryst " refer to BioCryst Pharmaceuticals, Inc. and, where appropriate, its subsidiaries. Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q (this "report") includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the "safe harbor" created in Section 21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events or performance are contained or incorporated by reference in this report. All statements other than statements of historical facts contained herein are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as "may," "will," "intends," "plans," "believes," "anticipates," "expects," "estimates," "predicts," "potential," the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking statements are principally contained in the " Risk Factors " and " Management's Discussion and Analysis of Financial Condition and Results of Operations " sections of this report, as well as any amendments we make to those sections in filings with the U.S. Securities and Exchange Commission ("SEC"). These forward-looking statements include, but are not limited to, statements about: the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX17725, avoralstat, and early-stage discovery programs, and our plans and anticipated timing regarding the same; our discovery and commercialization of best-in-c

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements BIOCRYST PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value amounts, Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 84,078 $ 104,713 Restricted cash 579 210 Short-term investments 128,795 216,137 Trade receivables 91,325 79,069 Inventory, net 5,232 8,087 Prepaid expenses and other current assets 16,502 13,752 Current assets held for sale 29,173 — Total current assets 355,684 421,968 Long-term inventory, net 23,390 23,187 Property and equipment, net 8,396 7,777 Long-term investments 39,669 20,323 Right of use assets 10,840 12,008 Other assets 4,387 5,157 Non-current assets held for sale 4,058 — Total assets $ 446,424 $ 490,420 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 5,567 $ 11,644 Accrued expenses 118,778 113,292 Operating lease liabilities 348 937 Finance lease liabilities 1,435 1,835 Royalty financing obligations 37,686 32,676 Current liabilities held for sale 26,423 — Total current liabilities 190,237 160,384 Operating lease liabilities 8,425 7,924 Finance lease liabilities 1,742 2,124 Royalty financing obligations 439,107 481,053 Secured term loan 194,366 314,869 Non-current liabilities held for sale 436 — Total liabilities 834,313 966,354 Stockholders' deficit: Preferred stock, $ 0.01 par value; shares authorized - 5,000 ; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.01 par value; shares authorized - 450,000 ; shares issued and outstanding – 210,522 at September 30, 2025 and 208,543 at December 31, 2024 2,105 2,085 Additional paid-in capital 1,360,890 1,291,100 Accumulated other comprehensive income 1,140 921 Accumulated deficit ( 1,752,024 ) ( 1,770,040 ) Total stockholders' deficit ( 387,889 ) ( 475,934 ) Total liabilities and stockholders' deficit $ 446,424 $ 490,420 See accompanying notes to conden

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing